Weight Loss Diet Not Needed With Exercise for Hip OA Pain
Overweight and obesity are considered risk factors for hip OA, yet there are conflicting data on whether weight loss reduces the need for hip joint replacement, researchers wrote in their August 4, 2025, report published in Annals of Internal Medicine .
In this study, researchers randomly assigned 101 people in Australia with a BMI above 27 to either 1) a dietitian-supported ketogenic very low-calorie diet plus a home-based exercise program supported by regular physiotherapy consultations or 2) the exercise program alone for 6 months .
All the participants were aged 50 years or older, had experienced significant hip pain for at least 3 months, and had radiographic evidence of femoral or acetabular osteophytes and joint space narrowing.
Despite the very-low-calorie-diet group losing a mean 8.5% more body weight than the exercise-only group, the study found no significant difference between the two groups in the primary outcome of hip pain severity at 6 or 12 months.
However, both groups did show a clinically significant reduction in hip pain severity at 6 months: a 2-point reduction on an 11-point scale in the exercise-only group and 2.8-point reduction in the diet plus exercise group. More people in the diet-plus-exercise group achieved a clinically relevant reduction in hip pain severity at 6 months than in the exercise-only group.
The study also found that those in the diet group had greater improvements in hip-related quality of life at 6 months compared to the exercise-only group, which persisted to 12 months.
Physiotherapist and study co-author Kim Bennell, PhD, director of the Centre for Health, Exercise and Sports Medicine at the University of Melbourne, Australia, said while the association between weight and symptoms or progression was strong with knee OA, there hadn't been many high-quality randomized controlled trials of weight loss for hip OA.
'The knee is not the hip; you can't necessarily generalize results from the knee to the hip,' Bennell told Medscape . 'We thought that it may not be as effective as you find at the knee because there may be different factors driving at the hip; biomechanical factors might be more important.'
Could the Results Direct Patients to Seek Surgery Sooner?
An accompanying editorial by rheumatologist Gillian Hawker, MD, of Women's College Hospital in Toronto and exercise physiologist Kristine Godziuk, PhD, of the University of California, San Francisco, raised the question of whether the use of pharmacotherapies for weight loss, such as the GLP-1 receptor agonists, might influence outcomes through changes in body composition.
Bennell said further studies were needed to explore whether greater weight loss than was achieved in this study might have led to better outcomes and over a longer period.
Commenting on the findings, rheumatologist Nancy E. Lane, MD, endowed professor of medicine and rheumatology and director of the Center for Musculoskeletal Health at UC Davis Health, Sacramento, California, said hip OA was much more related to underlying structural abnormalities than other forms of OA.
'There's no therapy that can make it better, because the hip joint, the shape of the hip — either the femoral head or the acetabular cup — is off and it's worn out,' Lane said to Medscape . 'There's no therapy for osteoarthritis of the hip, once it becomes painful.'
While weight loss would help to place less stress on the joint, it is a much smaller issue than for other joints, and being overweight in and of itself is not a risk factor for hip replacement, Lane said.
'It was really important to know that this type of exercise and weight loss wasn't going to have an effect on the hip,' she said, pointing out that this knowledge might help people with hip OA to get surgical treatment sooner, rather than being told to lose weight first. 'But to be very clear, that that's not the case in other joints, such as the knee, where these interventions make a difference,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Great Barrier Reef suffers most widespread bleaching on record
Australia's famed Great Barrier Reef has suffered its most widespread coral bleaching on record, according to a government report released Wednesday that warns the natural wonder is in dire health. Scientists documented the "most spatially extensive" bleaching since records began almost 40 years ago, driven by sweltering ocean temperatures in 2024 that triggered "unprecedented levels of heat stress". The Australian Institute of Marine Science surveyed the health of 124 coral reefs between August 2024 and May 2025. Northern and southern branches of the sprawling reef had seen the "largest annual decline in coral cover" ever recorded, the government agency found. Reefs had been battered by tropical cyclones and infestations of crown-of-thorns starfish that feast on coral. But the "number one cause is climate change," said the institute's research lead Mike Emslie. "There is no doubt about that," he told AFP. Often dubbed the world's largest living structure, the Great Barrier Reef is a 2,300 kilometre (1,400-mile) expanse of tropical corals that houses a stunning array of biodiversity. But repeated bleaching events have threatened to rob the tourist drawcard of its wonder, turning banks of once-vibrant coral a sickly white. Unusually warm tropical waters triggered widespread coral bleaching on the Great Barrier Reef in 2024 and in the first few months of 2025 -- the sixth such event in the past nine years. "The (Great Barrier Reef) experienced unprecedented levels of heat stress, which caused the most spatially extensive and severe bleaching recorded to date," the report found. Over the past two years a mass global bleaching event has drained the life from more than 80 percent of the world's coral reefs. Bleaching occurs when water temperatures rise forcing coral to expel the colourful microscopic algae, known as zooxanthellae, embedded in their tissues. If high temperatures persist, the coral can eventually turn white and die. Emslie said past coral growth would help cushion the record losses and that the Great Barrier Reef was still an "amazing place". - 'Worth fighting for' - "It is still worth fighting for. We can't throw our arms up and give up," he said. The report found a rapidly growing type of coral -- known as acropora -- had suffered the most. This coral is quick to grow, but is also one of the first to bleach. The report found that any recovery of the reef could take years and was dependent on future coral reproduction and minimal environmental disturbance. Richard Leck from the World Wildlife Fund compared the fluctuating health of the Great Barrier Reef to a "rollercoaster". "That is a sign of an ecosystem under incredible stress and what reef scientists are hugely concerned about is when the reef does not keep bouncing back the way it has," he told AFP. Leck said some coral reefs around the world were already beyond recovery, warning the Great Barrier Reef could suffer the same fate without ambitious and rapid climate action. The average sea surface temperature around Australia was the "highest on record" in 2024, according to Australian National University. Australia is currently developing its next round of emissions reduction targets, a key obligation under the landmark Paris climate agreement. The mining superpower remains one of the world's biggest coal exporters and continues to heavily subsidise its fossil fuel sectors. lec/sft/mtp
Medscape
5 minutes ago
- Medscape
NICE Urges Ongoing Support After Obesity Treatment
The National Institute for Health and Care Excellence (NICE) has released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications. This includes regular follow-up care, tailored action plans, and social support to help patients maintain their weight loss and avoid regaining weight. New Drugs Raise Need for Long-Term Support The new quality standard comes as weight-loss medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are being introduced on the NHS. An estimated 240,000 people are set to be offered tirzepatide over the next 3 years. The update addresses a critical gap in current care, noting that many people regain weight after treatment if they lack adequate support, with consequences for both physical and mental health. In England, 29% of adults are living with obesity and 64% of adults are classified as overweight or obese. Obesity-related illnesses are estimated to cost the NHS £11.4 billion a year and have a wider economic impact of £74.3 billion. Ensuring Continuity of Care The guidance stresses that weight management is a long-term process, not a one-time fix. It recommends that healthcare providers ensure continuity of care by monitoring patients for at least 12 months and offering tailored support to help maintain weight loss. This may include NHS Better Health resources and strategies for habit change, as well as practical adjustments at home or at work. The quality standard advocates for a shift from short-term interventions to strategies that foster lasting behavioural changes. It highlights the importance of self-monitoring and connecting patients with broader support networks, such as online communities, family-led initiatives, and local programmes. Guidance Implementation Professor Jonathan Benger, deputy chief executive of NICE, noted that weight management 'doesn't end when medication stops or when someone completes a behavioural programme,' adding that 'people need structured support to maintain the positive changes they've made.' The new guidance replaces three previous standards and reflects the most up-to-date strategies for tackling obesity through the healthcare system. Healthcare services are advised to begin implementing the standard immediately, with resource impact guidance available to assist in local adaptation.
Yahoo
40 minutes ago
- Yahoo
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ('efti'), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating efti in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab), the FDA agreed on the potential of efti in combination with KEYTRUDA to address the high unmet need in this CPS <1 patient segment and is supportive of the combination's further development. Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data. 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,' said Marc Voigt, CEO of Immutep. 'Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer,' added Mr Voigt. Project FrontRunner is an FDA Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to develop and seek approval of cancer drugs for advanced/metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients' lives. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy's progress in fighting cancer, anti-PD-1 therapy alone (without chemotherapy) is only approved for patients who express PD-L1 (CPS >1). All currently available treatment options for patients with PD-L1 CPS <1 include chemotherapy. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
